Vaccine Therapy in Treating Patients With Stage IV Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Vaccine therapy may be effective in treating stage IV melanoma.

PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

NCT00086866

Melanoma (Skin)

UNKNOWN PHASE2

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00089206

Intraocular Melanoma Melanoma (Skin)

COMPLETED PHASE2

Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma

NCT00074230

Melanoma (Skin)

COMPLETED PHASE1/PHASE2

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

NCT00037037

Melanoma (Skin)

UNKNOWN PHASE1

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00005633

Melanoma (Skin)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the feasibility of treating patients with stage IV melanoma with D1/3-MAGE-3-His fusion protein with SB-AS02B adjuvant.
* Determine the clinically confirmed response rates (partial and complete responses) of patients treated with this regimen.
* Determine the 6-month progression-free survival rate of patients treated with this regimen.
* Determine the qualitative and quantitative toxic effects of this regimen in these patients.
* Determine immune responses in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive D1/3-MAGE-3-His fusion protein emulsified in SB-AS02B adjuvant intramuscularly once every 3 weeks for a total of 12 weeks (4 injections). In the absence of disease progression or unacceptable toxicity, patients receive a second 12-week course beginning at week 16.

Patients are followed every 3 months for 1 year and then every 6 months for 2 years.

PROJECTED ACCRUAL: A total of 25-45 patients will be accrued for this study within 5-9 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma (Skin)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D1/3-MAGE-3-His fusion protein

Intervention Type BIOLOGICAL

SB-AS02B adjuvant

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed stage IV melanoma that is considered incurable by surgery, radiotherapy, or limb perfusion

* M1a or M1b disease
* Measurable disease outside prior field of limb perfusion
* Metastatic mucosal melanoma allowed
* MAGE-3 positive by reverse transcription polymerase chain reaction
* No uveal or choroidal primary melanoma
* No prior or concurrent brain metastases by CT scan or MRI of the brain

PATIENT CHARACTERISTICS:

Age

* Not specified

Performance status

* Zubrod 0-1

Life expectancy

* Not specified

Hematopoietic

* Not specified

Hepatic

* Hepatitis B surface antigen negative
* Hepatitis C negative
* No liver cirrhosis
* No unstable liver disease
* No coagulation disorders

Renal

* Not specified

Cardiovascular

* No major cardiovascular illness
* No myocardial infarction within the past 6 months

Pulmonary

* No major pulmonary illness

Other

* Not pregnant or nursing
* Fertile patients must use effective contraception
* HIV negative
* No AIDS or HIV-1-associated complex
* No chronic alcohol abuse or drug addiction
* No systemic infections
* No prior active autoimmune disease
* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer from which the patient is currently disease-free

PRIOR CONCURRENT THERAPY:

Biologic therapy

* At least 4 weeks since prior adjuvant biologic therapy
* No prior biologic therapy for stage IV melanoma
* No prior MAGE-3 peptide or protein vaccine preparation

Chemotherapy

* At least 4 weeks since prior adjuvant chemotherapy
* No prior chemotherapy for stage IV melanoma

Endocrine therapy

* Not specified

Radiotherapy

* At least 4 weeks since prior adjuvant radiotherapy

Surgery

* At least 4 weeks since prior surgery

Other

* See Disease Characteristics
* At least 3 weeks since prior limb perfusion and recovered
* At least 4 weeks since other prior adjuvant therapy
* No other prior therapy for stage IV melanoma

Eligible Sex

ALL

Accepts Healthy Volunteers

No